A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

November 4, 2019

Study Completion Date

November 4, 2019

Conditions

Healthy

Interventions

DRUG

Insulin Glargine

Administered SC

DRUG

Lantus

Administered SC

Trial Locations (1)

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT03555305 - A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter